The information contained in this section is intended for healthcare professional only.
Sanofi is focused on providing answers for patients in a number of pathologies, including in particular the prevention and treatment of thrombosis and cardiovascular diseases.
In thrombosis our leading medicines are:
Plavix® (clopidogrel bisulfate), an antiplatelet agent indicated in the secondary prevention of atherothrombosis-related events. It is commercialized in alliance with Bristol-Myers Squibb. Since 1998, it is estimated that at least 115 million people in 115 countries have been treated with Plavix®.
Clexane® (enoxaparin sodium), a low molecular weight heparin indicated in the prevention and treatment of deep vein thrombosis, and the treatment of unstable angina and non-Q-wave myocardial infarction in association with aspirin.
Clexane® has been used to treat more than 350 million patients in 100 countries. It was furthermore the market leader in the United States and in the main European countries in 2010*.
In the field of cardiovascular disease, our antiarrhythmic Multaq® (dronedarone) is used in patients with a history of atrial fibrillation (AF) or current non-permanent AF. It significantly reduces the risk of hospitalization due to cardiovascular causes.
Multaq® is authorized for marketing in more than 50 countries.
Renagel® (sevelamer hydrochloride) and Renvela® (sevelamer carbonate) are oral phosphate binders used by chronic kidney disease (CKD) patients on dialysis to treat a condition called hyperphosphatemia, or elevated phosphorus levels, which is associated with heart and bone disease. Renvela® is a second generation, buffered phosphate binder. Renvela® is also approved to control hyperphosphatenmia in CKD adults not on dialysis but with very high blood phosphorus levels.
In biosurgery: Synvisc® and Synvisc-One® (hylan G-F 20) are viscosupplements used to treat pain associated with osteoarthritis of certain joints. Synvisc® is a triple-injection product and Synvisc-One® is a next-generation, single-injection product. The principal viscosupplementation market is treatment of pain associated with osteoarthritis of the knee.
Our portfolio has many other specialties, including:
Stilnox® (zolpidem), for the treatment of insomnia.
Ambien CR® is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Telfast® (fexofenadine hydrochloride), for allergic rhinitis or urticaria.
Xatral® (alfuzosin hydrochloride), for the treatment of benign prostatic hyperplasia.
Actonel® (risedronate sodium), for patients with osteoporosis or Paget’s disease.
Tritace® (ramipril), for patients with high blood pressure, congestive heart failure or kidney disease.
Depalept® (sodium valproate) is a broad-spectrum anti-epileptic that has been prescribed for 40 years.
Arava® (leflunomide), a disease modifying antirheumatic drug (DMARD) helps improve rheumatoid arthritis and psoriatic arthritis symptoms such as joint swelling and tenderness.
Solian® An atypical antipsychotic drug, for the treatment of psychoses. Solian® has been shown to be effective in treating the symptoms of schizophrenia while possessing a positive metabolic profile.
* IMS sales 2010
Update: 19 December 2012